A Phase II, double‐blind, randomized, parallel group, dose‐finding study of the safety and tolerability of darexaban compared with warfarin in patients with non‐valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL‐2)

Autor: Lip, G.Y.H. *, Halperin, J.L., Petersen, P., Rodgers, G.M., Pall, D., Renfurm, R.W.
Zdroj: In Journal of Thrombosis and Haemostasis August 2015 13(8):1405-1413
Databáze: ScienceDirect
Externí odkaz: